Exelixis Inc
Research Exelixis Inc (EXEL) on Bullrun: valuation model: 1.0% undervalued, market cap USD 14.12B, P/E 17.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEXEL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal1.0% undervalued
- Market capUSD 14.12B
- P/E17.8
- Financial periodFY2026
- RevenueUSD 2.32B
- Revenue growth7.0%
- Net incomeUSD 782.60M
- Free cash flowUSD 875.84M
- Gross margin96.4%
Valuation Snapshot
Bullrun's latest valuation model marks Exelixis Inc as 1.0% undervalued; latest market cap is USD 14.12B; P/E is 17.8.
Peer valuation comparison
Latest P/E is 17.82x versus a Healthcare sector median of 24.46x (27.2% below).
Latest P/E is 17.82x versus a United States median of 24.87x (28.4% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | USD 2.32B | USD 782.60M | USD 875.84M | 96.4% | 2.78 | USD 482.49M | USD 165.93M | USD 2.16B |
| FY2025 | USD 2.17B | USD 521.30M | USD 671.54M | 96.5% | 1.76 | USD 217.37M | USD 173.04M | USD 2.24B |
| FY2024 | USD 2.17B | USD 521.27M | USD 633.79M | 96.5% | 3.05 | USD 217.37M | USD 190.82M | USD 2.24B |
| FY2023 | USD 1.83B | USD 207.80M | USD 292.86M | 96.0% | 0.65 | USD 262.99M | USD 189.94M | USD 2.26B |
| FY2022 | USD 1.61B | USD 182.30M | USD 334.91M | 96.4% | 0.56 | USD 501.20M | USD 161.02M | USD 2.49B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 14.12B | 17.8 | n/a | n/a |
| 2025 | 2025-12-31 | USD 11.50B | 15.8 | n/a | n/a |
| 2024 | 2024-12-31 | USD 9.38B | 18.8 | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.26B | 85.7 | n/a | n/a |
| 2022 | 2022-12-30 | USD 5.17B | 16.9 | n/a | n/a |
| 2021 | 2021-12-31 | USD 5.83B | 25.4 | n/a | n/a |
About Exelixis Inc
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Exelixis Inc overvalued or undervalued?
Bullrun's valuation model currently marks Exelixis Inc as 1.0% undervalued.
What is Exelixis Inc's market cap?
Exelixis Inc's market capitalization is USD 14.12B.
What is Exelixis Inc's P/E ratio?
Exelixis Inc's price-to-earnings (P/E) ratio is 17.8.
What does Exelixis Inc do?
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.